41st Annual Meeting of the American-Society-of-Clinical-Oncology Conference

related documents

• A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma.  Conferences
• A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCICCTG IND. 154.  Conferences
• A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC).  Conferences
• A phase II study of UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A Princess Margaret Phase II Consortium Trial  Conferences
• A phase II study of triapine in combination with gemcitabine in advanced pancreatic carcinoma: A Princess Margaret Hospital phase II consortium trial.  Conferences
• A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital [PMH] phase II consortium.  Conferences
• A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs).  Conferences
• Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen.  Conferences
• Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer (ACRC)  Conferences
• Evaluation of responsiveness to change to psychosocial group therapy (PGT) and to the process of dying of psychosocial and quality of life (QOL) measures.  Conferences
• HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial.  Conferences
• Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents  Conferences
• Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial.  Conferences
• Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors.  Conferences
• Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the princess margaret hospital [PMH] phase II consortium.  Conferences
• Phase II study of oblimersen sodium and rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma.  Conferences
• Pre-radiation R115777 in patients with newly diagnosed glioblastoma multiforme and residual enhancing disease  Conferences
• Predictive value of eTag dimerization assay in patients with metastatic colorectal cancer treated with erlotinib.  Conferences
• Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC).  Conferences
• Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC).  Conferences
• S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results  Conferences
• S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results.  Conferences
• Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome.  Conferences
• The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases.  Conferences
• The effect of zoledronic acid (Zol) dose and infusion rate on pharmacolkinetics (PK), pharmacodynamics (PD), and renal function in patients (pts) with multiple myeloma (MM) or prostate cancer (PC) and bone metastases.  Conferences
• The impact and perception of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of novel anticancer agents.  Conferences
• What are the supportive care service needs of recently diagnosed cancer patients? Results of a population based study  Conferences
• Willingness of older people with cancer to participate in cancer clinical trials is not a barrier to accrual.  Conferences